These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24445801)

  • 1. Alzheimer disease: chaperone protein clusterin is involved in amyloid-β-associated entorhinal atrophy in early AD.
    Malkki H
    Nat Rev Neurol; 2014 Feb; 10(2):60. PubMed ID: 24445801
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of clusterin in amyloid-β-associated neurodegeneration.
    Desikan RS; Thompson WK; Holland D; Hess CP; Brewer JB; Zetterberg H; Blennow K; Andreassen OA; McEvoy LK; Hyman BT; Dale AM;
    JAMA Neurol; 2014 Feb; 71(2):180-7. PubMed ID: 24378367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?
    Lehmann S; Gabelle A; Paquet C
    Alzheimers Dement; 2015 Sep; 11(9):1125-6. PubMed ID: 25457432
    [No Abstract]   [Full Text] [Related]  

  • 4. [Searched for and found: non-demented patients with Alzheimer's disease].
    Engelborghs S
    Tijdschr Psychiatr; 2011; 53(9):654-6. PubMed ID: 21898323
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebrospinal fluid opens a window on Alzheimer disease.
    Galasko D
    Arch Neurol; 1999 Jun; 56(6):655-6. PubMed ID: 10369301
    [No Abstract]   [Full Text] [Related]  

  • 6. A cerebrospinal fluid biosignature for the diagnosis of Alzheimer's disease.
    Barichello T; Giridharan VV; Dal-Pizzol F
    Braz J Psychiatry; 2019; 41(6):467-468. PubMed ID: 31826090
    [No Abstract]   [Full Text] [Related]  

  • 7. Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard.
    Vanderstichele HM; Shaw L; Vandijck M; Jeromin A; Zetterberg H; Blennow K; Teunissen C; Engelborghs S
    Clin Chem; 2013 Apr; 59(4):710-2. PubMed ID: 23355631
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
    Dean RA; Shaw LM
    Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
    [No Abstract]   [Full Text] [Related]  

  • 9. Tapping into the biology of Alzheimer disease.
    Knopman DS
    Neurology; 2011 Feb; 76(6):496-7. PubMed ID: 21228299
    [No Abstract]   [Full Text] [Related]  

  • 10. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
    Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
    Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
    Blennow K; Zetterberg H
    Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid biomarkers: pushing the limits of early detection.
    Rabinovici GD
    Brain; 2016 Apr; 139(Pt 4):1008-10. PubMed ID: 27012491
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?
    Papaliagkas VT
    Recent Pat CNS Drug Discov; 2013 Apr; 8(1):70-8. PubMed ID: 23489287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comments on the article by K. Buch et al. Tau protein: a potential biological marker for early detection of Alzheimer disease. Nervenarzt (1998) 69:379-385].
    Otto M; Wiltfang J; Poser S; Kornhuber J
    Nervenarzt; 1999 Jul; 70(7):668-70. PubMed ID: 10434268
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of amyloid-β, tau, and apolipoprotein E epsilon4 in Alzheimer disease: how is the team playing?
    Filippi M; Canu E; Agosta F
    AJNR Am J Neuroradiol; 2013 Mar; 34(3):511-2. PubMed ID: 22918432
    [No Abstract]   [Full Text] [Related]  

  • 17. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What does it mean to be 'amyloid-positive'?
    Fagan AM
    Brain; 2015 Mar; 138(Pt 3):514-6. PubMed ID: 25713403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sharpen that needle.
    Herskovits AZ; Growdon JH
    Arch Neurol; 2010 Aug; 67(8):918-20. PubMed ID: 20697041
    [No Abstract]   [Full Text] [Related]  

  • 20. Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.
    Andreasen N; Blennow K
    Peptides; 2002 Jul; 23(7):1205-14. PubMed ID: 12128078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.